ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 73 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,680,093 | -8.6% | 5,261,130 | +3.6% | 0.00% | 0.0% |
| Q2 2023 | $11,684,682 | -21.0% | 5,080,296 | +4.0% | 0.00% | -50.0% |
| Q1 2023 | $14,794,298 | +2524.9% | 4,882,607 | +1918.5% | 0.00% | – |
| Q4 2022 | $563,614 | +39.2% | 241,894 | +14.1% | 0.00% | – |
| Q3 2022 | $405,000 | -31.9% | 212,006 | -3.2% | 0.00% | – |
| Q2 2022 | $595,000 | +1.4% | 218,954 | +11.0% | 0.00% | – |
| Q1 2022 | $587,000 | -36.9% | 197,181 | -17.5% | 0.00% | – |
| Q4 2021 | $930,000 | -2.1% | 239,007 | +8.1% | 0.00% | – |
| Q3 2021 | $950,000 | +7.5% | 221,184 | -24.2% | 0.00% | – |
| Q2 2021 | $884,000 | -76.5% | 291,781 | -74.2% | 0.00% | -100.0% |
| Q1 2021 | $3,764,000 | -25.5% | 1,130,371 | -20.5% | 0.00% | 0.0% |
| Q4 2020 | $5,049,000 | -44.6% | 1,422,264 | -51.1% | 0.00% | -50.0% |
| Q3 2020 | $9,107,000 | +49.2% | 2,909,716 | -13.2% | 0.00% | +100.0% |
| Q2 2020 | $6,104,000 | +195.3% | 3,353,537 | +63.8% | 0.00% | 0.0% |
| Q1 2020 | $2,067,000 | -60.3% | 2,047,008 | +9.4% | 0.00% | 0.0% |
| Q4 2019 | $5,202,000 | +107.7% | 1,871,088 | +14.0% | 0.00% | 0.0% |
| Q3 2019 | $2,504,000 | -25.2% | 1,641,646 | +2.0% | 0.00% | 0.0% |
| Q2 2019 | $3,349,000 | -3.2% | 1,609,886 | +66.7% | 0.00% | 0.0% |
| Q1 2019 | $3,458,000 | -16.8% | 965,931 | -11.0% | 0.00% | 0.0% |
| Q4 2018 | $4,157,000 | -57.1% | 1,085,575 | +5.9% | 0.00% | -50.0% |
| Q3 2018 | $9,690,000 | +80.4% | 1,025,353 | +39.4% | 0.00% | +100.0% |
| Q2 2018 | $5,372,000 | +109.0% | 735,797 | +43.2% | 0.00% | 0.0% |
| Q1 2018 | $2,570,000 | -19.0% | 513,996 | -18.2% | 0.00% | 0.0% |
| Q4 2017 | $3,174,000 | +21.4% | 628,677 | +49.1% | 0.00% | 0.0% |
| Q3 2017 | $2,614,000 | +121.9% | 421,601 | +28.8% | 0.00% | – |
| Q2 2017 | $1,178,000 | -38.1% | 327,248 | -44.1% | 0.00% | – |
| Q1 2017 | $1,902,000 | +39.6% | 585,390 | +5.3% | 0.00% | – |
| Q4 2016 | $1,362,000 | +193.5% | 556,000 | +312.7% | 0.00% | – |
| Q3 2016 | $464,000 | +33.7% | 134,715 | +34.9% | 0.00% | – |
| Q2 2016 | $347,000 | +107.8% | 99,853 | +145.9% | 0.00% | – |
| Q1 2016 | $167,000 | +70.4% | 40,609 | +84.4% | 0.00% | – |
| Q4 2015 | $98,000 | -87.3% | 22,018 | -82.7% | 0.00% | – |
| Q3 2015 | $774,000 | – | 127,038 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,705,128 | $10,300,000 | 4.44% |
| RTW INVESTMENTS, LP | 5,666,754 | $15,754,000 | 0.59% |
| COWEN AND COMPANY, LLC | 926,200 | $2,575,000 | 0.22% |
| Hudson Bay Capital Management LP | 850,000 | $2,363,000 | 0.05% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,774,915 | $4,934,000 | 0.03% |
| Point72 Asset Management, L.P. | 1,897,284 | $5,274,000 | 0.03% |
| 683 Capital Management, LLC | 77,368 | $215,000 | 0.02% |
| Secure Asset Management, LLC | 10,000 | $28,000 | 0.02% |
| Qube Research & Technologies Ltd | 166,138 | $462,000 | 0.01% |
| Verition Fund Management LLC | 174,455 | $485,000 | 0.01% |